MedTrace Logo

Maraviroc and NeuroAIDS Pathogenesis

NCT02159027 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2021-08-30

No results posted yet for this study

Summary

Maraviroc is an antiretroviral medication that may help in improving mental function in HIV infected patients with mental problems by decreasing inflammatory tendencies. We will test this in a clinical trial of 42 HIV infected individuals with some mild to moderate mental problems who are already on HIV medications and doing well. We will add Maraviroc or a sugar pill to their HIV medications and see if mental function improves over 48 weeks. This study will be conducted at 2 sites in Hawaii and Puerto Rico.

Conditions

  • AIDS Dementia Complex

Interventions

DRUG

Maraviroc

Maraviroc administered twice daily, dosage based on concomitant medication being taken.

DRUG

Placebo

Maraviroc placebo administered twice daily, dosage based on concomitant medication being taken.

Sponsors & Collaborators

  • ViiV Healthcare

    collaborator INDUSTRY

  • University of Puerto Rico

    collaborator OTHER

  • University of Hawaii

    lead OTHER

Principal Investigators

  • Cecilia M. Shikuma, M.D. · University of Hawaii

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2019-02-28
Completion
2019-02-28

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02159027 on ClinicalTrials.gov